We use cookies to ensure that our site works correctly and provides you with the best experience. If you continue using our site without changing your browser settings, we'll assume that you agree to our use of cookies. Find out more about the cookies we use and how to manage them by reading our cookies policy. Hide

Current Issue

10th April 2019
Selected Chemistry & Industry magazine issue

Select an Issue


C&I e-books

C&I e-books

C&I apps

iOS App
Android App

Computing clean energy Computing clean energy

High performance computing is supercharging research into clean energy solutions.

Read the feature article


Green investing rules

Maria Burke, April 2019

New rules requiring financial asset managers, insurers and pension funds to disclose information relating to sustainability risks in their investments have been agreed by the European Parliament and EU Member States.


026 Eyes web

Eyes forward

Lou Reade, April 2019

Macular degeneration is a leading cause of blindness.


Product Focus

Metrohm Product Focus


There are no postcards for the issue of C&I Magazine which you have selected.

Click here to see other postcards from our international correspondents.



Kevin Burgess, April 2019

Collaboration by groups from Taiyuan, China, have discovered a dye they call POP, but I call ‘Cancer-Fluor’ because it lights up selectively in cancer cells over normal ones.


The post-antibiotic era

Dennis Rouvray, April 2019

We are currently witnessing the emergence of an ever-growing number of microbes that have become resistant to most or all existing drugs designed to act against them.



Neil Eisberg, April 2019

Given the focus on attracting students to participate in STEM subjects efficient and effective science communication is becoming even more important.


Future focus on challenges

Michael Kolk, April 2019

The chemical industry is one of the most successful manufacturing sectors in terms of historic value creation for its shareholders.


Business digest

April 2019

Chemicals major BASF has opened a research centre for catalyst and process development at its Verbund site.


Movers and Shakers

April 2019

Adam Crystal, most recently oncology lead at the Novartis Institute for BioMedical Research, is the new CMO of C4 Therapeutics.